Hemostasis Products Global Market Report 2026

Hemostasis products are medical substances or devices employed to control bleeding and facilitate clotting (hemostasis) across diverse medical contexts. These products play a critical role in the management of bleeding disorders, promotion of wound healing, and ensuring the proper functioning of the body's clotting mechanisms.

The primary categories of hemostasis products include topical hemostasis products, infusible hemostasis products, and advanced hemostasis products. Topical hemostasis products encompass medical substances or materials specifically designed to halt or regulate bleeding. They find applications in various scenarios such as trauma, surgery, hemophilia, myocardial infarction, and others, with major end-users including hospitals, clinics, and others.

Tariffs are influencing the hemostasis products market by increasing costs of imported biological materials, plasma-derived inputs, synthetic polymers, and precision manufacturing equipment used in topical, infusible, and advanced hemostatic products. Hospitals and surgical centers in North America and Europe are most affected due to reliance on imported specialty products, while Asia-Pacific faces higher production costs for export markets. These tariffs are raising treatment costs and impacting procurement decisions. However, they are also encouraging domestic production, regional sourcing of raw materials, and innovation in cost-effective hemostatic solutions.

The hemostasis products market research report is one of a series of new reports from The Business Research Company that provides hemostasis products market statistics, including hemostasis products industry global market size, regional shares, competitors with a hemostasis products market share, detailed hemostasis products market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis products industry. This hemostasis products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemostasis products market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing volume of surgical procedures, rising incidence of trauma cases, growing prevalence of bleeding disorders, expansion of hospital surgical capacities, availability of diverse hemostatic formulations.

The hemostasis products market size is expected to see strong growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing adoption of advanced biological and synthetic agents, rising demand for minimally invasive surgical solutions, expansion of trauma care infrastructure, growing focus on faster wound healing outcomes, increasing innovation in clotting technologies. Major trends in the forecast period include increasing adoption of advanced hemostatic agents, rising use of topical and sealant-based products, growing demand for rapid bleeding control solutions, expansion of hemostasis applications in surgery and trauma, enhanced focus on biocompatible materials.

The rising prevalence of cardiac disorders is expected to propel the growth of the hemostasis products market moving forward. Cardiac disorders encompass a wide range of medical conditions and diseases that impact the heart and blood vessels. Hemostasis products play a critical role in managing bleeding related to cardiac disorders, as well as in their prevention and treatment. These products can help minimize blood loss, thereby reducing the need for blood transfusions and the associated complications in cardiac disorders. For instance, in January 2024, the American Heart Association, a U.S.-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, reflecting a 4.0% increase from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiac disorders is contributing to the growth of the hemostasis products market going forward.

Major companies operating in the hemostasis products market are increasingly concentrating on the development of next-generation topical hemostatic powders, including advanced polysaccharide-based powder systems engineered to achieve rapid bleeding control in surgical and emergency care environments. Topical hemostatic powders are passive, absorbable agents that facilitate clot formation by concentrating blood components and accelerating the body's natural coagulation process at the site of bleeding. For instance, in July 2023, Baxter International Inc., a US-based medical products company, introduced PERCLOT Absorbable Hemostatic Powder in the United States, a ready-to-use, plant-derived hemostatic solution designed for managing mild bleeding across a broad range of surgical procedures. The product offers rapid wettability, compatibility with laparoscopic applicators, and wide procedural adaptability, allowing surgeons to control intraoperative bleeding effectively while enhancing ease of use and procedural efficiency.

In May 2025, Merit Medical Systems Inc., a US-based medical device company specializing in interventional and surgical products, acquired Biolife Delaware LLC for approximately US$120 million. Through this acquisition, Merit Medical Systems seeks to expand and reinforce its hemostasis solutions portfolio by incorporating Biolife's StatSeal and WoundSeal topical hemostatic product lines, strengthen its capabilities in post-procedural bleeding management across vascular access and wound care settings, and increase its footprint in the hemostasis products market. Biolife Delaware LLC is a US-based producer of topical hemostatic products designed for rapid external bleeding control in vascular access and wound care applications.

Major companies operating in the hemostasis products market are Pfizer Inc., Medtronic plc, Johnson And Johnson Pvt. Ltd., Stryker Corporation, Baxter International Inc., F. Hoffmann-La Roche Ltd., BBraun Melsungen AG, Fresenius Kabi AG, Grifols S.A., Terumo BCT Inc., Smith And Nephew plc, Ethicon Suture Laboratories, Cook Medical, Teleflex Incorporated, Integra LifeSciences Corporation, Haemonetics Corporation, Z-Medica LLC, Tricol Biomedical, Hem Con Medical Technologies Inc., Hemostasis LLC, CuraMedical BV, Ethicon Suture Laboratories

North America was the largest region in the hemostasis products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemostasis products market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemostasis products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemostasis products market consists of sales of hemostatic agents, hemostatic powders, hemostatic sponges, collagen, oxidized regenerated cellulose, gelatin, polysaccharide, flowable complex, thrombin complex, fibrin complex, synthetic sealants, and fresh frozen plasma. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemostasis Products Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hemostasis products market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemostasis products ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemostasis products market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Topical Hemostasis Product; Infusible Hemostasis Product; Advanced Hemostasis Product
• 2) By Application: Trauma; Surgery; Hemophilia; Myocardial Infarction; Other Applications
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Topical Hemostasis Product: Hemostatic Agents; Tissue Sealants; Fibrin Sealants
• 2) By Infusible Hemostasis Product: Platelet-Rich Plasma (PRP); Coagulation Factors; Prothrombin Complex Concentrates
• 3) By Advanced Hemostasis Product: Biological Adhesives; Synthetic Hemostatic Agents; Hemostatic Dressings
• Companies Mentioned: Pfizer Inc.; Medtronic plc; Johnson And Johnson Pvt. Ltd.; Stryker Corporation; Baxter International Inc.; F. Hoffmann-La Roche Ltd.; BBraun Melsungen AG; Fresenius Kabi AG; Grifols S.A.; Terumo BCT Inc.; Smith And Nephew plc; Ethicon Suture Laboratories; Cook Medical; Teleflex Incorporated; Integra LifeSciences Corporation; Haemonetics Corporation; Z-Medica LLC; Tricol Biomedical; Hem Con Medical Technologies Inc.; Hemostasis LLC; CuraMedical BV; Ethicon Suture Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.